Daiichi Sankyo Company, Limited

Symbol: DSKYF

PNK

33.8

USD

Market price today

  • 50.2616

    P/E Ratio

  • 0.0468

    PEG Ratio

  • 64.81B

    MRK Cap

  • 0.00%

    DIV Yield

Daiichi Sankyo Company, Limited (DSKYF) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.74%

Operating Profit Margin

0.12%

Net Profit Margin

0.13%

Return on Assets

0.06%

Return on Equity

0.13%

Return on Capital Employed

0.07%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Sunao Manabe D.V.M., Ph.D.
Full-time employees:17435
City:Tokyo
Address:3-5-1, Nihonbashi-honcho
IPO:2008-06-24
CIK:

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

General Outlook

When we look at how much money they make before expenses, they keep 0.741% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.115%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.125%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.058% return, is a testament to Daiichi Sankyo Company, Limited's adeptness in optimizing resource deployment. Daiichi Sankyo Company, Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.125%. Furthermore, the proficiency of Daiichi Sankyo Company, Limited in capital utilization is underscored by a remarkable 0.067% return on capital employed.

Stock Prices

Daiichi Sankyo Company, Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $34.84, while its low point bottomed out at $34.16. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Daiichi Sankyo Company, Limited's stock market.

Liquidity Ratios

Analyzing DSKYF liquidity ratios reveals its financial health of the firm. The current ratio of 300.53% gauges short-term asset coverage for liabilities. The quick ratio (152.25%) assesses immediate liquidity, while the cash ratio (89.46%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio300.53%
Quick Ratio152.25%
Cash Ratio89.46%

Profitability Ratios

DSKYF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 14.80% underscores its earnings before tax deductions. The effective tax rate stands at 15.28%, revealing its tax efficiency. The net income per EBT, 84.68%, and the EBT per EBIT, 128.69%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 11.50%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin14.80%
Effective Tax Rate15.28%
Net Income per EBT84.68%
EBT per EBIT128.69%
EBIT per Revenue11.50%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.01, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 352.65% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding152
Days of Inventory Outstanding385
Operating Cycle488.53
Days of Payables Outstanding490
Cash Conversion Cycle-1
Receivables Turnover3.53
Payables Turnover0.75
Inventory Turnover0.95
Fixed Asset Turnover3.80
Asset Turnover0.46

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 312.31, and free cash flow per share, 248.32, depict cash generation on a per-share basis. The cash per share value, 337.29, showcases liquidity position. A payout ratio of 0.34 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.37, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share312.31
Free Cash Flow per Share248.32
Cash per Share337.29
Payout Ratio0.34
Operating Cash Flow Sales Ratio0.37
Free Cash Flow to Operating Cash Flow Ratio0.80
Cash Flow Coverage Ratio5.89
Short Term Coverage Ratio1501.90
Capital Expenditure Coverage Ratio4.88
Dividend Paid and Capex Coverage Ratio3.15
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.94%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.66%, and total debt to capitalization, 5.68%, ratios shed light on its capital structure. An interest coverage of 10.14 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.94%
Debt Equity Ratio0.06
Long Term Debt to Capitalization5.66%
Total Debt to Capitalization5.68%
Interest Coverage10.14
Cash Flow to Debt Ratio5.89
Company Equity Multiplier2.05

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 835.33, provides a glimpse into top-line earnings distributed across each share. Net income per share, 104.69, reflects the portion of profit attributed to each share. The book value per share, 880.44, represents the net asset value distributed per share, while the tangible book value per share, 736.30, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share835.33
Net Income Per Share104.69
Book Value Per Share880.44
Tangible Book Value Per Share736.30
Shareholders Equity Per Share880.44
Interest Debt Per Share56.19
Capex Per Share-64.04

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 25.28%, indicates top-line expansion, while the gross profit growth, 29.66%, reveals profitability trends. EBIT growth, 51.21%, and operating income growth, 51.21%, offer insights into operational profitability progression. The net income growth, 83.84%, showcases bottom-line expansion, and the EPS growth, 83.80%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth25.28%
Gross Profit Growth29.66%
EBIT Growth51.21%
Operating Income Growth51.21%
Net Income Growth83.84%
EPS Growth83.80%
EPS Diluted Growth83.83%
Weighted Average Shares Growth0.02%
Dividends per Share Growth22.80%
Operating Cash Flow Growth423.31%
Free Cash Flow Growth910.58%
10-Year Revenue Growth per Share96.20%
5-Year Revenue Growth per Share74.61%
3-Year Revenue Growth per Share68.31%
10-Year Operating CF Growth per Share1669.32%
5-Year Operating CF Growth per Share559.94%
3-Year Operating CF Growth per Share215.34%
10-Year Net Income Growth per Share262.78%
5-Year Net Income Growth per Share117.80%
3-Year Net Income Growth per Share167.29%
10-Year Shareholders Equity Growth per Share89.74%
5-Year Shareholders Equity Growth per Share36.92%
3-Year Shareholders Equity Growth per Share34.23%
10-Year Dividend per Share Growth per Share74.92%
3-Year Dividend per Share Growth per Share38.62%
Receivables Growth43.54%
Inventory Growth45.26%
Asset Growth37.95%
Book Value per Share Growth16.74%
Debt Growth-47.26%
R&D Expense Growth6.91%
SGA Expenses Growth41.06%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 8,596,101,514,031.955, captures the company's total value, considering both debt and equity. Income quality, 2.99, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 8.00%, indicates the value of non-physical assets, and capex to operating cash flow, -20.49%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value8,596,101,514,031.955
Income Quality2.99
Research and Development to Revenue22.80%
Intangibles to Total Assets8.00%
Capex to Operating Cash Flow-20.49%
Capex to Revenue-7.67%
Capex to Depreciation-205.87%
Graham Number1440.09
Return on Tangible Assets6.30%
Graham Net Net-295.01
Working Capital1,450,625,000,000
Tangible Asset Value1,411,808,000,000
Net Current Asset Value401,495,000,000
Average Receivables385,306,000,000
Average Payables318,758,000,000
Average Inventory369,859,500,000
Days Sales Outstanding104
Days Payables Outstanding490
Days of Inventory On Hand385
ROIC8.72%
ROE0.12%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.98, and the price to book ratio, 5.98, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.29, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 21.16, and price to operating cash flows, 16.84, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.98
Price to Book Ratio5.98
Price to Sales Ratio6.29
Price Cash Flow Ratio16.84
Price Earnings to Growth Ratio0.05
Enterprise Value Multiple43.58
Price Fair Value5.98
Price to Operating Cash Flow Ratio16.84
Price to Free Cash Flows Ratio21.16
Price to Tangible Book Ratio5.42
Enterprise Value to Sales5.37
Enterprise Value Over EBITDA35.25
EV to Operating Cash Flow14.34
Earnings Yield2.20%
Free Cash Flow Yield5.21%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Daiichi Sankyo Company, Limited (DSKYF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 50.262 in 2024.

What is the ticker symbol of Daiichi Sankyo Company, Limited stock?

The ticker symbol of Daiichi Sankyo Company, Limited stock is DSKYF.

What is company IPO date?

IPO date of Daiichi Sankyo Company, Limited is 2008-06-24.

What is company current share price?

Current share price is 33.800 USD.

What is stock market cap today?

The market cap of stock today is 64811454742.000.

What is PEG ratio in 2024?

The current 0.047 is 0.047 in 2024.

What is the number of employees in 2024?

In 2024 the company has 17435.